31 results about "Artery dissection" patented technology

The invention discloses a vertebral artery dissection risk assessment method and system, and relates to the technical field of risk assessment, and the method comprises the steps: collecting ultrasonic dynamic blood parameter data of a vertebral artery of a patient; based on the ultrasonic dynamic blood parameter data, constructing a local blood flow kinetic energy disturbance time sequence diagram by adopting a hemodynamics time sequence analysis method, and performing time sequence prediction to generate a blood flow function disturbance prediction result; dynamically adjusting a risk score threshold by adopting a reinforcement learning algorithm, combining the adjusted risk score threshold with a blood flow function disturbance prediction result, and generating a personalized vertebral artery dissection risk score according to a risk score calculation model; and generating a vertebral artery dissection risk assessment result by using a multi-modal fusion mechanism in combination with the personalized vertebral artery dissection risk score and the multi-source heterogeneous medical feature set. According to the method, the patient static characteristics and the future disturbance trend serve as input, the optimal risk score threshold value is dynamically selected, and the personalized score is generated according to the disturbance threshold exceeding proportion and time weight information.

The present invention proposes a multi-branch stent for aortic dissection distal aneurysm zoning, belonging to the field of medical device technology. It includes a main covered stent, which is composed of a covering and a main stent. The main covered stent is sequentially arranged from one end to the other end as an upper half, a waist transition section and a lower half; the upper and lower parts of the upper half in the vertical direction are respectively a soft zone and a hard zone; the upper and lower parts of the lower half in the vertical direction are respectively a hard zone and a soft zone; the upper and lower parts are respectively provided with two embedded branch stents; the embedded branch stent in the upper half is used to reconstruct the celiac trunk and the superior mesenteric artery, and the embedded branch stent in the lower half is used to reconstruct the bilateral renal arteries. The present invention increases the adaptability of the anchoring areas at both ends of the main covered stent to the blood vessels, prevents the rupture of the inner membrane sheet of the distal rupture, improves the adhesion of the main covered stent to the tube wall, reduces the incidence of type I internal leakage, reduces the incidence of new stent-induced ruptures after surgery, and can reconstruct visceral arteries at the same time.

The invention discloses a characteristic data identification method for aortic dissection and acute myocardial infarction. The method comprises the following steps: acquiring infrared and Raman spectrum data of sample blood of the aortic dissection and the acute myocardial infarction; establishing an infrared set and a Raman spectrum characteristic data set through a convolutional neural network; performing feature fusion on the data of the infrared spectrum fine feature data set and the Raman spectrum fine feature data set by adopting a multi-head self-attention mechanism and a cross attention mechanism to obtain an aortic dissection and acute myocardial infarction feature data set; according to the aortic dissection and acute myocardial infarction characteristic data set, characteristic data identification of infrared spectrum data and Raman spectrum data of newly collected blood is carried out. According to the method, spectral features are extracted through two convolutional layers, modal features are optimized in combination with self-attention and cross attention mechanisms, complementary information is fused, and the accuracy and stability of feature recognition of aortic dissection and acute myocardial infarction are improved.

The utility model relates to a bigeminal carotid artery balloon blocking catheter, and belongs to the technical field of surgical instruments and equipment. The bigeminal carotid artery balloon blocking catheter comprises a circulation tube and a balloon hose, wherein the circulation tube is of an integrated structure and comprises a main tube, a branch tube and a switch valve; one end of the main pipe is connected with two groups of branch pipes; one end of the branch pipe is connected with an adapter through a switch valve; and a balloon hose is inserted into the adapter. The bigeminal carotid artery balloon blocking catheter is compact in structure and ingenious in design, blood transfusion can be conducted on the left carotid artery and the right carotid artery at the same time under the cooperation of an extracorporeal circulation machine, meanwhile, the blocking function is achieved, the problems that an existing A-type aortic dissection operation is inconvenient to operate and high in risk, and medical resources are wasted are solved, and the bigeminal carotid artery balloon blocking catheter is particularly suitable for being used in the A-type aortic dissection operation.

The application provides an aortic dissection rupture sealing device, which comprises a body having a hollow flow channel extending along the axial direction of the body, the hollow flow channel penetrating the rupture for conducting the true lumen of the aorta and the branch blood vessel, and the body being used for connecting a stent located in the branch blood vessel; and an anchoring part arranged on the body and surrounding the hollow flow channel, and anchored to the surrounding intima at the rupture, so as to prevent the fluid from conducting between the true lumen and the false lumen formed at the rupture. By using the above scheme, the rupture sealing effect can be improved, the continuous expansion of the false lumen caused by the incomplete rupture sealing and the residual liquid leakage can be avoided, and the blood supply stability of the branch blood vessel can be ensured, so that the blood supply demand of the internal organs, the spinal cord and the like supplied by the branch blood vessel can be met.

The application provides an aortic dissection rupture sealing device, which comprises an anchoring part, a hollow flow channel, and an intima around the rupture, so as to prevent the fluid communication between the true lumen of the aorta and the false lumen formed at the rupture; a stent, which is adjustably coupled to the anchoring part, has a connecting end and a free end, and at least the free end of the stent is located in a branch blood vessel; and the stent has a hollow structure in communication with the hollow flow channel and is supported in the branch blood vessel to communicate the true lumen and the branch blood vessel. The above scheme can avoid the continuous expansion of the false lumen caused by the incomplete sealing of the rupture and residual shunt, and at the same time, the blood supply of the blood vessel channel is retained to ensure the stability of the blood supply of the branch blood vessel, which is beneficial to meet the blood supply demand of the internal organs, spinal cord and the like supplied by the branch blood vessel.

The invention belongs to the technical field of medicines, and particularly relates to application of muscone in preparation of a medicine for preventing or treating aortic dissection and the medicine. The invention relates to application of muscone in preparation of a medicine for preventing or treating aortic dissection. The medicine comprises one or more of the following effects: inhibiting aortic dilatation and dissection; aortic dilatation and dissection rupture are inhibited; the infiltration of macrophages in the aorta is inhibited; the apoptosis of aortic smooth muscle cells is inhibited; the effect of reducing inflammatory cytokines in the aorta is achieved; retrogressive lesions of the aortic medial membrane are inhibited; the degradation of the aortic dissection extracellular matrix is inhibited.

The present invention provides an application of OTUD7B as a target in the preparation of products for diagnosing and / or preventing and treating aortic dissection, belonging to the technical field of disease diagnosis and treatment. The results show that, compared with healthy people, the expression of OTUD7B is significantly up-regulated in both mice with BAPN-induced aortic dissection model and patients with aortic dissection, that is, the detection of the expression of OTUD7B can be used for diagnosing aortic dissection. Mice with OTUD7B knockdown in vascular fibroblasts are less likely to develop aortic dissection and elastic fiber degradation under BAPN induction, while mice with high expression of OTUD7B in vascular fibroblasts are more likely to develop aortic dissection and elastic fiber degradation under BAPN induction, indicating that OTUD7B inhibitors can be used for preventing and / or treating aortic dissection. Therefore, OTUD7B provides a target for diagnosing and / or preventing and treating aortic dissection.

The present invention discloses the application of p55γ as a therapeutic target for aortic dissection, belonging to the technical field of biomedicine. Overexpression of p55γ inhibits the formation of aortic dissection and the degradation of elastic fibers induced by BAPN in mice; while knockdown of p55γ in vascular smooth muscle cells promotes the formation of aortic dissection and the degradation of elastic fibers induced by BAPN. Mechanistically, p55γ plays a role by maintaining the contractile phenotype of vascular smooth muscle, and knockdown of p55γ promotes the transformation of vascular smooth muscle cells from the contractile type to the synthetic type. The present invention uses p55γ as a target for screening drugs for preventing and / or treating aortic dissection, so that the screened drugs can effectively prevent and / or treat aortic dissection, providing a new target for the treatment of aortic dissection.

The invention relates to the technical field of molecular biology and medicine, and particularly discloses application of WWP1 in preparation of a medicine for preventing and / or treating aortic dissection, and relates to application of WWP1 in prevention and treatment of aortic dissection. Molecular biology experiment detection of the expression level of the WWP1 in aortic dissection aortic tissue and the expression level of smooth muscle cell contraction and secretion phenotype marker genes proves that the expression level of the WWP1 in an aortic dissection aortic tissue sample is obviously higher than that of a control aortic tissue; and overexpression of the WWP1 in an animal model significantly reduces the morbidity of the aortic dissection and improves the contraction phenotype of the aortic smooth muscle, i.e., the protectiveness of the WWP1 in the morbidity process of the aortic dissection is improved. Based on the research result, the WWP1 can be used as a drug target for screening, preventing and treating the aortic dissection.

The present invention discloses molecular markers for differential diagnosis of aortic dissection and acute myocardial infarction and their applications. The molecular markers include gene SIGLEC8, gene CCL2, gene PRR35, gene FAM240C, gene TNFAIP8L3, and gene ASTL. The genes SIGLEC8, CCL2, PRR35, FAM240C, TNFAIP8L3, and ASTL protected by the present invention can be used as biomarkers for differentiating aortic dissection and acute myocardial infarction. The markers protected by the present invention have the potential for good differential diagnosis of patients with aortic dissection and acute myocardial infarction, and have good diagnostic efficacy, which can distinguish patients with aortic dissection from those with acute myocardial infarction, enabling patients to receive effective treatment in a timely manner.

The invention discloses application of theaflavin in preparation of drugs for preventing and treating aortic dissection. According to the application of theaflavin provided by the invention, the theaflavin mediates macrophage polarization and inflammation imbalance by regulating and controlling an NLRP3 small body pathway, participates in attack of aortic dissection, and can effectively relieve occurrence and development of aortic dissection.

This invention discloses a targeted nanocarrier for the diagnosis and treatment of arterial dissection and its preparation method. The targeted nanocarrier is composed of a macromolecular prodrug self-assembly constructed by covalently linking the NLRP3 inhibitor CY-09 and oxidized fucoidan through phenylboronic acid ester bonds and imine bonds, using iodine contrast agent ICA as a connecting bridge. The targeted nanocarrier prepared by this invention possesses good stability, drug release characteristics, excellent dissection targeting, and dual responsiveness to reactive oxygen species and acidic microenvironments, demonstrating significant imaging diagnostic and therapeutic effects on arterial dissection.

The invention discloses application of KAT7 as a target spot in treatment of aortic aneurysm and dissection. According to the application, an AngII-induced aortic aneurysm mouse model is applied, the treatment effect of the KAT7 inhibitor WM3835 on aortic aneurysm / dissection is detected through mouse survival rate, aortic aneurysm occurrence rate, aorta width, blood vessel staining and WB staining indexes, and the WM3835 can slow down the occurrence and progress of aortic aneurysm, reduce the occurrence of aortic dissection and improve the survival rate of aortic aneurysm / dissection, so that the KAT7 inhibitor WM3835 can be used for treating aortic aneurysm / dissection. And a new target and a new medicine are provided for clinically treating aorta and dissection of aortic aneurysm. The KAT7 inhibitor WM3835 provided by the invention is a brand new drug treatment means for treating aortic aneurysm and dissection, is an important supplement for operative treatment of aortic aneurysm / dissection, and has important clinical significance.

The application provides an aortic dissection postoperative cardiopulmonary function rehabilitation device, and belongs to the technical field of cardiopulmonary rehabilitation. The aortic dissection postoperative cardiopulmonary function rehabilitation device comprises a fixing structure and a clamping structure, the fixing structure comprises a first gasket, a second gasket, a U-shaped frame, a fixing assembly, a rectangular shell, an adjusting assembly, an arc-shaped clamping plate and two connecting belts, the first gasket is rotationally connected with the second gasket, the U-shaped frame is slidingly connected with the first gasket, the fixing assembly is connected with the U-shaped frame, and the rectangular shell is connected with the fixing assembly. In the application, the aortic dissection postoperative cardiopulmonary function rehabilitation device can conveniently avoid foot deviation during rehabilitation training, improve the training effect, and conveniently adjust the position of the U-shaped frame according to the height of a user, thereby improving the practicability of the device.

The present invention relates to the use of T-5224 in preventing aortic dissection disease in mice. In the present invention, the AP-1 inhibitor T-5224 with a duration of effective concentration for 2 weeks and 3 weeks respectively is used to intervene in mice with an arterial dissection model induced by BAPN. The results show that the aortic dilation rate and rupture rate of the mice are significantly reduced; the survival condition of the mice is significantly improved. The present invention provides a new and effective method for preventing AD, further provides a basis for guiding rational clinical medication, and provides a new idea for the prevention of AD disease clinically.

This invention provides a method and system for predicting the risk of aortic remodeling after aortic dissection, comprising the following steps: receiving CTA images of the patient's chest and abdomen at multiple time points, such as preoperative and short or mid-operative postoperatively, and obtaining aortic segmentation results based on the CTA images; obtaining the displacement field of each voxel point between the two time points based on the aortic segmentation results, and obtaining vascular deformation mapping results based on the displacement field; extracting multi-dimensional features from the three-dimensional aortic segmentation model and the vascular deformation mapping results respectively; and predicting the risk of adverse aortic remodeling after surgery based on the multi-dimensional features. The beneficial effects of this invention are: by comprehensively utilizing multi-dimensional, dynamic, and static features, the prediction model constructed by this invention theoretically has higher discrimination and calibration than existing single-index models. Therefore, this invention can detect early, local abnormal deformations that cannot be detected by traditional diameter measurement, significantly advancing the risk identification time point.

Disclosed in the present invention are an automatic detection method and system for coronary artery dissections. The method comprises: first, collecting clinical coronary artery angiography images, and processing the images to form a data set, so as to train and verify a YOLOv8 model; processing a coronary artery angiography image needing to be tested, and then inputting same into the YOLOv8 model for the identification and localization of an FL in the image; using a constructed SO(2)-UNet model to perform feature extraction and semantic segmentation on coronary arteries in a located region of the image after identification and localization, and accurately segmenting coronary vessels; and further identifying a dissection region in the segmented coronary vessels, and visually presenting same. In the present invention, YOLOv8 is used to perform object detection, a large number of images are quickly and accurately tested in a short time, and coronary artery dissections in the images are automatically identified to realize an automatic detection process, thereby significantly improving the efficiency and accuracy of diagnosis.

The invention provides a balloon perfusion catheter used in aortic dissection, and relates to the technical field of medical instruments.The balloon perfusion catheter comprises a perfusion catheter body and balloons evenly distributed on the periphery of the perfusion catheter body, a perfusion inlet is formed in the near end of the perfusion catheter body, and a perfusion outlet is formed in the far end of the perfusion catheter body; three balloons are distributed on the periphery of the perfusion catheter body, the near-end balloon is a blocking balloon, the middle balloon is a threaded balloon, and the far-end balloon is an expansion balloon. The balloon perfusion catheter can provide continuous perfusion in an aortic dissection operation, remarkably reduces or avoids long-time circulation stopping, effectively prevents perfusion blood from flowing back to an operation area from the inside and the outside of the trunk support through the synergistic effect of the three balloons, provides a clear operation view field for surgeons, and improves the operation efficiency. And accurate suture and reconstruction are facilitated, and the accuracy and safety of an operation are improved.

Use of a serine / arginine-rich splicing factor 1 (SRSF1) as a therapeutic target for aortic dissection is provided, which belonging to the technical field of biomedicine. The SRSF1 can be used as a target to screen a drug for preventing and / or treating aortic dissection. SRSF1 expression is upregulated in both β-aminopropionitrile (BAPN)-induced aortic dissection model mice and aortic dissection patients. Mice with SRSF1 knockdown in vascular smooth muscle cells (VSMCs) are less susceptible to aortic dissection and elastic fiber degradation induced by BAPN. Mice with high expression of SRSF1 in VSMCs are more susceptible to aortic dissection and elastic fiber degradation induced by BAPN. Mechanistically, the SRSF1 can regulate the inflammatory phenotype of vascular smooth muscle and promote the degradation of vascular extracellular matrix. Knocking down the SRSF1 may improve the above phenomenon, thereby providing a new target for the treatment of aortic dissection.

The present application provides a method and device for classifying key cell types and subtypes of thoracic aortic dissection. The method according to the present application includes: pre-processing tissue samples of thoracic aortic dissection and normal controls to obtain cell types; determining suspected key cell types of thoracic aortic dissection based on the ratio of cell types in aortic dissection and normal control tissue samples, obtaining cell subtypes corresponding to suspected key cell types of thoracic aortic dissection based on gene expression data of suspected key cell types; determining suspected key cell subtypes of thoracic aortic dissection based on cell subtypes corresponding to suspected key cell types of thoracic aortic dissection; determining key cell types and subtypes of arterial dissection based on suspected key cell types of thoracic aortic dissection and the suspected key cell subtypes of thoracic aortic dissection. The present application can determine key cell types and subtypes of thoracic aortic dissection.

The invention relates to the technical field of medical instruments, in particular to secondary injury prevention blocking forceps for aortic dissection surgery, which comprise a handheld cylinder, a first wrench and a second wrench are arranged on a holding part of the handheld cylinder, and a clamping head is detachably connected to the head of the handheld cylinder. The clamping head is provided with two elastic clamping pieces capable of elastically deforming, the two elastic clamping pieces are in an arc-shaped state when clamping a blood vessel, and the suspended ends of the two elastic clamping pieces are close to each other after capturing a target blood vessel, so that the blood vessel is locked between the two arc-shaped clamping arms; therefore, the situation that the surrounding blood vessels are affected due to the fact that traditional blocking forceps are opened by a large angle is avoided, the surrounding blood vessels can be prevented from being affected, then damage to the surrounding blood vessels is avoided, then the two elastic clamping pieces are gradually converted into the straight clamping arms, and the blood vessels are gradually and stably clamped to block blood flow in the blood vessels.

The application provides an aortic dissection rupture sealing device, which comprises an anchoring part, a hollow flow channel, and an intima around the rupture, so as to prevent the fluid communication between the true lumen of the aorta and the false lumen formed at the rupture; a stent, which is adjustably coupled to the anchoring part, has a connecting end and a free end, and at least the free end of the stent is located in a branch blood vessel; and the stent has a hollow structure in communication with the hollow flow channel and is supported in the branch blood vessel to communicate the true lumen and the branch blood vessel. The above scheme can avoid the continuous expansion of the false lumen caused by the incomplete sealing of the rupture and residual shunt, and at the same time, the blood supply of the blood vessel channel is retained to ensure the stability of the blood supply of the branch blood vessel, which is beneficial to meet the blood supply demand of the internal organs, spinal cord and the like supplied by the branch blood vessel.

The invention discloses application of terazosin in preparation of drugs or health care products for preventing and / or treating aortic dissection, and relates to the technical field of medicines. Animal test and clinical research are carried out on the current clinical common drug terazosin, and the result shows that the small dose of terazosin can effectively prevent and treat the aortic dissection, so that important technical support is provided for early treatment or prevention of aortic related diseases. Experimental and clinical research results also prove that the terazosin with the dosage of 0.5 mg has a good effect in the aspects of improving the vascular elasticity and reducing the vascular pulse wave conduction velocity, the dosage can be greatly reduced, the medication cost can be saved, and the medical burden of a patient can be relieved. Meanwhile, due to the fact that the dosage of terazosin used in the human body is extremely low, adverse side effects related to terazosin are basically eradicated.

An explainable artificial intelligence system for early prediction of missed severe diagnoses in intensive care unit patients is provided. The system comprises a data processing module configured to receive and process electronic health record data including patient demographics, vital signs, laboratory results, and diagnostic codes. A machine learning module with ensemble, deep learning, and large language models analyzes processed data to predict likelihood of severe diagnoses including acute myocardial infarction, acute pulmonary embolism, bacterial pneumonia, aortic dissection, meningitis, spinal abscess, bacterial endocarditis, and arterial thromboembolism. An explainability module generates feature importance rankings and provides interpretable explanations for predictions.

This invention discloses a method and system for predicting in-hospital mortality risk in patients undergoing acute type A aortic dissection surgery based on interpretable machine learning. The method includes: collecting clinical data from patients undergoing acute type A aortic dissection surgery and constructing an original feature dataset; evaluating the feature importance of each feature in the original feature dataset to obtain a score for each feature, and filtering based on the scores to obtain a core feature dataset; inputting the core feature dataset corresponding to the target patient into a pre-trained in-hospital mortality risk prediction model, and outputting the predicted in-hospital mortality probability of the target patient; calculating the feature contribution corresponding to the predicted in-hospital mortality probability, and generating an interpretable result for the mortality risk prediction of the target patient. The technical solution of this invention can reduce model complexity, improve model generalization ability, and improve prediction accuracy and interpretability.

The invention belongs to the technical field of biological pharmacy, and provides an application of an HMGB2 inhibitor in preparation of a medicine for treating aortic dissection, and the application is that the HMGB2 inhibitor is applied to preparation of the medicine for treating aortic dissection. An aortic dissection model is established through animal experiments, and the treatment effect of the HMGB2 inhibitor is evaluated; results show that the HMGB2 inhibitor can inhibit development of the aortic dissection by improving the degree of vascular injury, blocking nucleation and secretion of HMGB2 cells, delaying the aging process of VSMCs and reducing HMGB2-mediated inflammation amplification effect and matrix degradation to achieve the purpose of treating the aortic dissection.

The present invention discloses a device for simulating the hemodynamics of aortic dissection. The device comprises a servo drive device, a ventricular simulation device, an artificial valve device, an aortic dissection model, a damping plate, a one-way valve and a liquid storage system, which are sequentially connected through a systemic circulation pipeline and fixed to a support plate with a transparent outer cover and an aortic support plate; the servo drive device, a pressure sensor, a flow meter and a high-speed camera are externally connected to a computer control system. After the servo drive device pulsates, the fluid medium flows from the liquid storage device through the ventricular simulation device and reaches the ascending aorta root of the aortic dissection model under the one-way action of the artificial valve device. The fluid medium then flows back into the liquid storage system through the damping plate and one-way valve built into the aortic arch three-branch artery circuit and the descending aorta circuit. A high-speed camera collects the hemodynamic changes during the dissection rupture and tearing process. The device achieves real-time hemodynamic simulation by changing the model type, blood pressure, fluid viscosity and posture.

The invention discloses a biomarker for predicting the onset risk of aortic dissection, a kit and application. The invention provides application of a reagent for detecting the SERPINE1 level of peripheral blood in preparation of products for aortic dissection attack risk prediction, early screening, diagnosis or curative effect monitoring. The marker and the related detection kit can be used for predicting the occurrence risk of the aortic dissection, and are not limited to diagnosis of the occurred dissection; the method is suitable for screening and dynamic follow-up visit of high-risk groups; the operation is simple and convenient, and a detection sample can be obtained through peripheral blood; the aortic wall pathological remodeling and fibrinolytic / matrix stability change can be reflected. Clinical sample verification shows that the method for predicting the onset risk of the aortic dissection through the SERPINE1 level of the peripheral blood has relatively high sensitivity and specificity, and relatively high clinical application value and application prospect are shown.

The present invention provides a pharmaceutical composition containing ticagrelor for use in reducing or preventing thromboembolic events before and / or during and / or after neurovascular arterial procedures in a patient requiring the use of the pharmaceutical composition containing ticagrelor, comprising administering an effective amount of the pharmaceutical composition containing ticagrelor to a patient, wherein the pharmaceutical composition is an aqueous solution containing a solubilizing agent for ticagrelor and the pharmaceutical composition is administered intravenously; wherein the patient suffers from a cerebral aneurysm, cerebral arteriosclerosis, cervical arteriosclerosis, neurovascular carotid dissection or carotid dissection.